Using artificial intelligence, digital therapeutics, and genomics, these are the top five startups that are disrupting U.S. healthcare today.
Data is at the heart of applicable genomics. As the volume and depth of genomic data grows, bioinformaticians are translating the data into interpretable patterns leading to new biological insight.
To understand the biology of diseased organs, researchers can use different types of molecular data. One of the biggest computational challenges at the moment is integrating these multiple data types.
Computational researchers have developed a computer program which has revealed a previously unknown combination of drugs that may be the answer to triple-negative breast cancer.
When it comes to understanding what makes people tick—and get sick—medical science has long assumed that the bigger the sample of human subjects, the better. New research suggests this big data approach may be wildly off the mark.
Genomic data company, Fabric Genomics have said its proprietary clinical genomics platform has been selected by 10 new commercial partners across Africa, Asia, Europe and North America.
Probably not. But there is an increasing demand for people with data and computing skills, and the life sciences sector in California may be losing the battle with Silicon Valley for those people.
Microbiotica has entered into a multi-year strategic collaboration with Genentech, a Roche company, to discover, develop, and commercialise biomarkers, targets, and medicines for inflammatory bowel disease.
The study of viral ecology is taking major leaps forward with the use of long-read sequencing and viral metagenomics. On this webinar we discuss how MinION technology is bringing scientists closer to high-throughput single-virus genomics from environmental samples.
A security breach at DNA testing website MyHeritage have leaked the data of over 92 million users, the company said on Monday.
People’s medical and health history might become more than just a blueprint for doctor’s actions, now that blockchain start-up Nebula Genomics, and Hong Kong-based Longenesis are partnering up.